Key takeaways:

Health care providers must assume a proactive role in reducing harm from 7-OH.

This includes prioritizing patient education, implementing screening protocols and offering or referring patients to treatment.

The FDA recently proposed scheduling synthetic and concentrated forms of 7-hydroxymitragynine, or 7-OH, under the Controlled Substances Act.

This represents an important step in balancing public health protection with recognition of the potential therapeutic benefits of the kratom plant in its natural form.

What is 7-OH?

Unlike raw kratom leaf, which contains little to no 7-OH, kratom extracts and concentrates are highly processed products, often engineered to amplify potency through elevated levels of 7-OH, and sometimes added synthetic 7-OH. These formulations

See Full Page